BETA

36 Amendments of Philippe JUVIN related to 2010/2153(INI)

Amendment 2 #
Motion for a resolution
Citation 23
– having regard to the report by the French Senate's committee of inquiry into influenza A entitled ‘Influenza A (H1N1)v: reflections on the first pandemic of the 21st Century’, published on 29 July 201012 , 12 http://www.senat.fr/notice- rapport/2009/r09-685-1-notice.htmldeleted
2010/12/20
Committee: ENVI
Amendment 7 #
Motion for a resolution
Recital A
A. whereas the national and international health authorities, including the WHO, were aware as early as May 2009 that the H1N1 influenza was not virulent, with this moderate virulence being confirmed by the very low mortality rate observed as a result of this influenza ‘pandemic’ in 1 http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/print.html comparison with the officially recognised figures for seasonal influenza,deleted
2010/12/20
Committee: ENVI
Amendment 12 #
Motion for a resolution
Recital A a (new)
Aa. whereas, under the International Health Regulations (IHR) – a legal instrument binding on the states parties to it – the remit of the WHO includes public health surveillance, coordinating international public health measures and, in relation to potentially pandemic viruses, determining current phases of alert on a scale of one to six,
2010/12/20
Committee: ENVI
Amendment 13 #
Motion for a resolution
Recital A b (new)
Ab. whereas the phases of a global pandemic are determined in accordance with the provisions of the IHR and in consultation with other organisations and institutions and with the Member States affected,
2010/12/20
Committee: ENVI
Amendment 14 #
Motion for a resolution
Recital B
B. whereas the criteria for defining a ‘pandemic’, adopted by the WHO in 2009 and based solely on the propagation of the virus while discounting the severity of the infection, distorted the meaning of the word ‘pandemic’ and triggered a false alarm worldwide, with that alarmism giving rise to inappropriate public health decisions and a disproportionate response among the public and administrations of the European Union and its Member States,deleted
2010/12/20
Committee: ENVI
Amendment 22 #
Motion for a resolution
Recital B a (new)
Ba. Considering the high degree of unforeseeability and severity of how the pandemic was going to unfold, always with the possibility that the pandemic might worsen in Europe, as it did in 1918 and 1968;
2010/12/20
Committee: ENVI
Amendment 28 #
Motion for a resolution
Recital C
C. whereas the exaggerated costs arising from the management of this crisis in the Member States are primarily a direct consequence of the EU's lack of independence and critical acumen in relation to the risk evaluation conducted by the WHO,deleted
2010/12/20
Committee: ENVI
Amendment 40 #
Motion for a resolution
Recital E
E. whereas this systematic vaccination strategy is based essentially on an approach that relies on blind faith in the effectiveness of influenza vaccines, without taking into account scientific data that contradict that belief (see Cochrane journals), and the majority of the studies available on the efficacy of the medicinal products, including vaccines, have been conducted by pharmaceutical companies, meaning that no objective proof has been provided of the efficacy of influenza vaccines,deleted
2010/12/20
Committee: ENVI
Amendment 56 #
Motion for a resolution
Recital G
G. whereas significant changes are required to the current healthcare system in the EU and its Member States in order to achieve general public health objectives, as opposed to a purely pharmacological approach,deleted
2010/12/20
Committee: ENVI
Amendment 60 #
Motion for a resolution
Recital I
I. whereas confidence in vaccines against H1N1 influenza was also undermined by the partial transfer from the manufacturer to the Member State, in the purchase contracts, of liability for any side effects,deleted
2010/12/20
Committee: ENVI
Amendment 69 #
Motion for a resolution
Recital J
J. whereas information has been garnered by various parliamentary committees and evaluation missions conducted in the EU Member States on the action taken to combat H1N1 influenza,deleted
2010/12/20
Committee: ENVI
Amendment 74 #
Motion for a resolution
Subheading 1
INDEPENDENCECOOPERATION
2010/12/20
Committee: ENVI
Amendment 75 #
Motion for a resolution
Paragraph 1
1. Calls forRequests that the prevention plans established in the EU and its Member States to be revised to make them sufficiently autonomousin order to gain in effectiveness, in coherence and of flexible to be adapted as swiftly as possible and on a case by case basis to the actual risk, based not least on the latest scientific information availableility by a better coordination of the instruments installed but also of the scientific data available. For this purpose, it is in particular advisable to reinforce the mandate of the Committee of Public Health whose action should be more based on an intergovernmental level and whose composition should reflect a better representativeness of the executive decisions;
2010/12/20
Committee: ENVI
Amendment 80 #
Motion for a resolution
Paragraph 1 a (new)
1a. Emphasises the need to reinforce cooperation between Member States within the EU in the management of the response to a pandemic, within the framework of WHO, according to the International Health Regulation of 2005 ;
2010/12/20
Committee: ENVI
Amendment 81 #
Motion for a resolution
Paragraph 1 b (new)
1b. Wants to reinforce the collaboration between Member States by ensuring coherent risk assessment and risk management for fast evolving threats at EU level by putting in place, where necessary, additional structures and coordination mechanisms;
2010/12/20
Committee: ENVI
Amendment 82 #
Motion for a resolution
Paragraph 1 c (new)
1c. Is delighted about the fact that the Commission committed itself studying the possibility of a revision and, should this happen, a long-term reinforcement of the legal base of Health Security Committee;
2010/12/20
Committee: ENVI
Amendment 84 #
Motion for a resolution
Paragraph 1 e (new)
1e. Urges the WHO to revise the definition of a pandemic, taking into consideration, when a virus is detected, not only its geographical spread but also its severity;
2010/12/20
Committee: ENVI
Amendment 86 #
Motion for a resolution
Paragraph 1 g (new)
1g. Calls on the Member States to involve health professionals more closely at every stage in the preparation and application of strategies for preventing and combating pandemics;
2010/12/20
Committee: ENVI
Amendment 87 #
Motion for a resolution
Paragraph 1 h (new)
1h. Urges the European Union to allot more means to the research and the development while conforming to the objective which it assigned to allocate 3% of the European GDP to the R & D; more specifically claim an increase in the investments dedicated to a better evaluation and anticipation of the impact of an influenza virus as well in period between pandemic as at the beginning of a pandemic;
2010/12/20
Committee: ENVI
Amendment 88 #
Motion for a resolution
Paragraph 1 i (new)
1i. Welcomes the Commission's commitment to develop a mechanism for joint procurement of vaccines and antiviral medication which allows Member States, on a voluntary basis, a common acquisition of these products or common approaches to contract negotiations with the pharmaceutical industry; Recalls that only the seeking for joint solutions for a common purchasing of vaccines and antiviral medications will ensure equitable access, at the lowest price for the Member States;
2010/12/20
Committee: ENVI
Amendment 89 #
Motion for a resolution
Paragraph 1 j (new)
1j. Calls for continued investment in national epidemiological, serological and virological surveillance centres;
2010/12/20
Committee: ENVI
Amendment 97 #
Motion for a resolution
Paragraph 3
3. Demands that robust, crediblePoints out the need for and effective scientific procedures be introduced for the evaluation of medicinal products recommended in the event of health emergencies, and more particularly in genuine pandemic, independent, transparent and balanced scientific report for the evaluation of the drugs including in health emergency situations;
2010/12/20
Committee: ENVI
Amendment 100 #
Motion for a resolution
Paragraph 3 a (new)
3a. Underscores the need for studies independent of the pharmaceutical companies on vaccines and antiviral medications, including with regard to the monitoring of vaccination coverage;
2010/12/20
Committee: ENVI
Amendment 101 #
Motion for a resolution
Paragraph 4
4. Calls for immediate clarifications on the effectiveness of the influenza vaccination strategies recommended in the EU, given the weight of evidence casting doubt on their effectiveness, the absence of reliable data guaranteeing that effectiveness and the lingering uncertainties surrounding their benefit- risk profile;deleted
2010/12/20
Committee: ENVI
Amendment 116 #
Motion for a resolution
Paragraph 5
5. Calls in particular on the EMA to reviewimprove the accelerated authorisation procedures for the placing on the market of medicinal products designed to respond to a health crisis, in order to ensure correct assessment of the benefit-risk profile associated with the use of those medicinal products;
2010/12/20
Committee: ENVI
Amendment 117 #
Motion for a resolution
Paragraph 5 a (new)
5a. Wants to ensure that the scientific experts have no financial or other interests in the pharmaceutical industry that could affect their impartiality; Request the development of a European code of conduct relating to the exercise of the scientific function of expert in any European authority in charge of safety, of the management and the anticipation of the risks ; require that each expert subscribe to the ethical principles of this code of conduct before any taking up the duties ;
2010/12/20
Committee: ENVI
Amendment 118 #
Motion for a resolution
Paragraph 5 b (new)
5b. Asks that experts who are involved in the pharmaceutical sector could be consulted but should be excluded from decision-making ;
2010/12/20
Committee: ENVI
Amendment 119 #
Motion for a resolution
Paragraph 5 c (new)
5c. Requests the installation of a definition of the conflict of interest which is common to all the European agencies ;
2010/12/20
Committee: ENVI
Amendment 146 #
Motion for a resolution
Paragraph 10
10. Calls for full liability for the quality, safety and effectiveness of a medicinal product to rest with the manufacturer, while taking account of the different legal arrangements for compulsory vaccinations;
2010/12/20
Committee: ENVI
Amendment 150 #
Motion for a resolution
Paragraph 10 a (new)
10a. Is aware of the need to communicate more clearly and transparently to help the publics to facilitate the risk communication; Underlines the necessity to arrive to only one and single message bound for the citizens as soon as the health hazard was evaluated ; insists on the importance of consistent communication of the Member States regarding the informative contents of the message (as for the nature of the virus, with the nature of the risk and in the manner of securing and curing);
2010/12/20
Committee: ENVI
Amendment 151 #
Motion for a resolution
Paragraph 10 b (new)
10b. Requires a global European strategic approach for the so-called “at-risk” groups on how to reach them and communicate with them in case of pandemics;
2010/12/20
Committee: ENVI
Amendment 152 #
Motion for a resolution
Paragraph 10 c (new)
10c. Calls to build relationships of trust with the media concerned with disseminating public health messages; Request the setting-up of a select group of available experts to answer questions from journalists at all times, as well as the availability of a spokesperson;
2010/12/20
Committee: ENVI
Amendment 153 #
Motion for a resolution
Paragraph 10 d (new)
10d. Stresses the need for accountability of information professionals and the prudence required in the processing of health information messages a fortiori in the context of a pandemic;
2010/12/20
Committee: ENVI
Amendment 156 #
Motion for a resolution
Subheading 3 a (new)
Within the framework of the common and liable management of supply of vaccines, request to think over the possibility of easing the access of developing countries to vaccinal products in case of a pandemic;
2010/12/20
Committee: ENVI
Amendment 158 #
Motion for a resolution
Paragraph 11
11. Demands precise definition ofRequests to specify and clarify the roles, duties, remits, limits, relations and responsibilities of the key actors and the structures of management of the medical threats at the level of the EU which are the European Commission, the ECDC, the EMA and the Member States and also of more informal entities such as the Health Security Committee, the HEOF and the ‘public health’ group, composed of senior officials able to intervene in the decision- making process regarding the management of a health crisis;
2010/12/20
Committee: ENVI
Amendment 163 #
Motion for a resolution
Paragraph 12
12. Expresses its approval of the introduction of a procedure enabling the Member States to make group purchases of anti-viral vaccines and medicinal products on a voluntary basis where the positive benefit-risk profile of their preventive/therapeutic effect is clearly demonstrated and indisputable, in order to obtain, for a given product, advantageous rates approaching its cost price;deleted
2010/12/20
Committee: ENVI